ADAM™ : Intelligent In-Silico Discovery & Molecule Screening
Transition from traditional, slow-moving lab trials to high-velocity In-silico research. Adam empowers R&D teams to identify promising bioactive compounds and optimize leads with unprecedented precision, cutting early-stage discovery timelines by up to 70%.
Bridging the Gap Between Ideation and Lead Optimization
In sectors like Nutraceuticals and Cosmetics, the challenge isn't just finding a molecule—it's proving it is safe, effective, and innovative. Adam serves as your digital scientific partner during the most critical phase of the R&D lifecycle.
AI-Powered Target Identification
Scan vast molecular libraries to find bioactive compounds that match your specific functional goals.
Advanced Toxicological Safety Profiling
Predict safety and receptorial interactions digitally, reducing the need for costly and ethically sensitive animal testing.
Precision Hit-to-Lead Optimization
Refine your most promising "hits" into stable, innovative leads ready for clinical evaluation.
Precision Tools for Modern Researchers
In-Silico Molecular Screening
High-throughput screening that overcomes the limits of manual computational chemistry
Predictive Toxicology
In-depth receptorial profiling to ensure early safety and mitigate late-stage failure risks.
Data Integrity & Traceability
Built on the same "Swiss Secure Vault" standards as the rest of the HubMed ecosystem, ensuring your IP is protected from day one.
Vertical Discovery Solutions
Nutraceuticals
Rapidly identify ingredients that support specific health claims.
Cosmetics
Design next-generation skincare ingredients with a focus on safety and sustainable innovation.
Medical Devices
Evaluate material biocompatibility and bioactive coatings before entering the clinical phase.
Frequently asked questions
Here are some common questions about Adam.
By using intelligent receptorial profiling, Adam filters out unsafe or ineffective candidates earlier than traditional methods, ensuring that only the highest-quality leads proceed to clinical evaluation.
Yes. Adam’s In-silico safety profiling allows cosmetic and nutraceutical formulators to predict human toxicological responses digitally, aligning with global trends toward ethical and sustainable R&D.
Adam is part of the End-to-End HubMed Ecosystem. Data generated during the discovery phase flows seamlessly into Medea, providing a continuous "Digital Thread" for your Clinical Evaluation Reports and Technical Files.
Start Your Discovery Revolution Today
Join the R&D teams who are exploring new therapeutic avenues with speed and confidence.